Back to top

Image: Bigstock

Should You Buy Stoke Therapeutics, Inc. (STOK) After Golden Cross?

Read MoreHide Full Article

Stoke Therapeutics, Inc. (STOK - Free Report) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, STOK's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross."

There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-term moving average. Typically, a golden cross involves the 50-day and the 200-day moving averages, since bigger time periods tend to form stronger breakouts.

There are three stages to a golden cross. First, there must be a downtrend in a stock's price that eventually bottoms out. Then, the stock's shorter moving average crosses over its longer moving average, triggering a positive trend reversal. The third stage is when a stock continues the upward momentum to higher prices.

This kind of chart pattern is the opposite of a death cross, which is a technical event that suggests future bearish price movement.

STOK has rallied 11.1% over the past four weeks, and the company is a #3 (Hold) on the Zacks Rank at the moment. This combination indicates STOK could be poised for a breakout.

The bullish case only gets stronger once investors take into account STOK's positive earnings outlook for the current quarter. There have been 7 upwards revisions compared to none lower over the past 60 days, and the Zacks Consensus Estimate has moved up as well.

With a winning combination of earnings estimate revisions and hitting a key technical level, investors should keep their eye on STOK for more gains in the near future.


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Stoke Therapeutics, Inc. (STOK) - free report >>

Published in